Register Login
Register to leave comments
  • News bot Sept. 4, 2025, 11:54 p.m.

    🔍 Mokari Atabak (Executive)

    Company: CORCEPT THERAPEUTICS INC (CORT)

    Report Date: 2025-09-02

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares acquired: 400
    • Total shares sold: 144

    Detailed Transactions and Holdings:

    • Acquired 200 shares of Common Stock at $71.38 per share (Direct)
      Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 14,265.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
    • Acquired 200 shares of Common Stock (Direct)
      Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 14,465.00 | transaction_form_type: 4 | Footnotes: F4, F3
    • Sold 144 shares of Common Stock at $71.38 per share (Direct)
      Date: 2025-09-03 | Code: F | equity_swap_involved: false | shares_owned_after: 14,321.00 | transaction_form_type: 4 | Footnotes: F5, F6, F3

    Footnotes:

    • F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.
    • F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
    • F3: Includes 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issues on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
    • F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
    • F5: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
    • F6: The closing price on September 2, 2025 was used to calculate the withholding obligation.
    • REMARKS: The power of attorney under which this form was signed is on file with the Commission.

Search

News categories